

---

## Lytix Biopharma Q2 2025 - Extended Update

Redeye comments on Lytix Biopharma's Q2 report 2025 in an extended update. During the quarter, progress was made with recruitment in NeoLIPA. Verrica plans a pivotal phase III study as the next development step in basal cell carcinoma.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Lytix Biopharma Q2 2025 - Extended Update**